{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T03:18:40Z","timestamp":1779938320650,"version":"3.53.1"},"reference-count":43,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2020,1,21]],"date-time":"2020-01-21T00:00:00Z","timestamp":1579564800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Novartis Pharma AG"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0227557","type":"journal-article","created":{"date-parts":[[2020,1,21]],"date-time":"2020-01-21T13:28:42Z","timestamp":1579613322000},"page":"e0227557","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":24,"title":["Real-world effectiveness and safety of ranibizumab for the treatment of myopic choroidal neovascularization: Results from the LUMINOUS study"],"prefix":"10.1371","volume":"15","author":[{"given":"Robin D.","family":"Hamilton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6192-1557","authenticated-orcid":true,"given":"Andreas","family":"Clemens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5896-5313","authenticated-orcid":true,"given":"Angelo Maria","family":"Minnella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy Y. Y.","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiji","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chui Ming","family":"Gemmy Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nor Fariza","family":"Ngah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelia","family":"Dunger-Baldauf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank G.","family":"Holz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the LUMINOUS study group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2020,1,21]]},"reference":[{"issue":"1","key":"pone.0227557.ref001","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00417-012-2022-8","article-title":"Long-term effect of intravitreal injection of anti-VEGF agent for visual acuity and chorioretinal atrophy progression in myopic choroidal neovascularization","volume":"251","author":"A Oishi","year":"2013","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"3","key":"pone.0227557.ref002","doi-asserted-by":"crossref","first-page":"M20","DOI":"10.1167\/iovs.18-25957","article-title":"IMI\u2014Defining and Classifying Myopia: A Proposed Set of Standards for Clinical and Epidemiologic Studies","volume":"60","author":"DI Flitcroft","year":"2019","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"5","key":"pone.0227557.ref003","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.preteyeres.2012.04.001","article-title":"Choroidal neovascularization in pathological myopia","volume":"31","author":"K Neelam","year":"2012","journal-title":"Prog Retin Eye Res"},{"issue":"7","key":"pone.0227557.ref004","doi-asserted-by":"crossref","first-page":"3721","DOI":"10.1167\/iovs.09-3493","article-title":"Ocular risk factors for choroidal neovascularization in pathologic myopia","volume":"51","author":"Y Ikuno","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"pone.0227557.ref005","article-title":"Epidemiology and disease burden of pathologic myopia and myopic choroidal neovascularization: an evidence-based systematic review","volume":"157","author":"TY Wong","year":"2014","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"pone.0227557.ref006","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1001\/archopht.122.4.495","article-title":"The prevalence of refractive errors among adults in the United States, Western Europe, and Australia","volume":"122","author":"JH Kempen","year":"2004","journal-title":"Arch Ophthalmol"},{"key":"pone.0227557.ref007","unstructured":"Chan NS, Teo K Fau\u2014Cheung CMG, Cheung CM. Epidemiology and Diagnosis of Myopic Choroidal Neovascularization in Asia. (1542-233X (Electronic))."},{"issue":"12","key":"pone.0227557.ref008","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/S0161-6420(84)34116-1","article-title":"Natural history of choroidal neovascularization in degenerative myopia","volume":"91","author":"MP Avila","year":"1984","journal-title":"Ophthalmology"},{"issue":"8","key":"pone.0227557.ref009","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/S0161-6420(96)30515-0","article-title":"Etiology of choroidal neovascularization in young patients","volume":"103","author":"SY Cohen","year":"1996","journal-title":"Ophthalmology"},{"issue":"1","key":"pone.0227557.ref010","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1159\/000446027","article-title":"Ranibizumab in Myopic Choroidal Neovascularization: A Subgroup Analysis by Ethnicity, Age, and Ocular Characteristics in RADIANCE","volume":"236","author":"FG Holz","year":"2016","journal-title":"Ophthalmologica"},{"issue":"7347","key":"pone.0227557.ref011","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1136\/bmj.324.7347.1195","article-title":"Myopia","volume":"324","author":"DR Fredrick","year":"2002","journal-title":"BMJ"},{"issue":"9","key":"pone.0227557.ref012","first-page":"2486","article-title":"Prevalence and risk factors for refractive errors in adult Chinese in Singapore","volume":"41","author":"TY Wong","year":"2000","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"6","key":"pone.0227557.ref013","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1097\/APO.0000000000000234","article-title":"Epidemiology of Pathologic Myopia in Asia and Worldwide","volume":"5","author":"YL Wong","year":"2016","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"issue":"4","key":"pone.0227557.ref014","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1517\/14712598.2016.1132696","article-title":"The role of anti-VEGF agents in myopic choroidal neovascularization: Current standards and future outlook","volume":"16","author":"MR Munk","year":"2016","journal-title":"Expert Opin Biol Ther"},{"issue":"8","key":"pone.0227557.ref015","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1097\/IAE.0b013e31826956e4","article-title":"Anti-vascular endothelial growth factor therapy for myopic choroidal neovascularization: do we need more evidence?","volume":"32","author":"TY Lai","year":"2012","journal-title":"Retina"},{"issue":"9","key":"pone.0227557.ref016","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1097\/IAE.0000000000001227","article-title":"MYOPIC CHOROIDAL NEOVASCULARIZATION: Diagnosis and Treatment","volume":"36","author":"TY Lai","year":"2016","journal-title":"Retina"},{"key":"pone.0227557.ref017","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.preteyeres.2017.10.005","article-title":"Diagnosis and treatment guideline for myopic choroidal neovascularization due to pathologic myopia","volume":"63","author":"K Ohno-Matsui","year":"2018","journal-title":"Prog Retin Eye Res"},{"issue":"6","key":"pone.0227557.ref018","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/eye.2013.8","article-title":"Ranibizumab for the treatment of choroidal neovascularisation secondary to pathological myopia: interim analysis of the REPAIR study","volume":"27","author":"A Tufail","year":"2013","journal-title":"Eye (Lond)"},{"issue":"3","key":"pone.0227557.ref019","doi-asserted-by":"crossref","DOI":"10.1016\/j.ophtha.2013.10.023","article-title":"RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia","volume":"121","author":"S Wolf","year":"2014","journal-title":"Ophthalmology"},{"key":"pone.0227557.ref020","unstructured":"FDA Approves Genentech\u2019s Lucentis (Ranibizumab Injection) for Myopic Choroidal Neovascularization [Press Release]. South San Francisco, 2017 [cited 2019 13 March]. Available from: https:\/\/www.gene.com\/media\/press-releases\/14651\/2017-01-05\/fda-approves-genentechslucentis-ranibiz"},{"issue":"7","key":"pone.0227557.ref021","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.ophtha.2017.02.018","article-title":"Treatment Patterns for Myopic Choroidal Neovascularization in the United States: Analysis of the IRIS Registry","volume":"124","author":"J Willis","year":"2017","journal-title":"Ophthalmology"},{"issue":"1","key":"pone.0227557.ref022","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12886-017-0401-y","article-title":"Demographics of patients receiving Intravitreal anti-VEGF treatment in real-world practice: healthcare research data versus randomized controlled trials","volume":"17","author":"F Ziemssen","year":"2017","journal-title":"BMC Ophthalmol"},{"key":"pone.0227557.ref023","unstructured":"European Medical Agency [cited 2019 13 March]. Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Summary_of_opinion\/human\/000715\/WC500143795.pdf"},{"key":"pone.0227557.ref024","unstructured":"Christos Haritoglou\u2014Augenklinik Herzog Carl Theodor M, Katrin Lorenz\u2014Augenklinik und Poliklinik der Universit\u00e4tsmedizin Mainz M, Kristina Markova\u2014Augenklinik Herzog Carl Theodor M, Matthias Iwersen\u2014Alcon Pharmaceuticals\u2013Novartis Pharma GmbH N, Ulrike Michel\u2014Alcon Pharmaceuticals\u2013Novartis Pharma GmbH N, Judith Becker\u2014Augen\u00e4rzte im Basteicenter U, et al. 31 Internationaler Kongress der Deutschen Ophthalmochirurgen (DOC), 1406\u201316062018, N\u00fcrnberg."},{"issue":"12","key":"pone.0227557.ref025","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1038\/s41433-018-0192-2","article-title":"Real-world data on ranibizumab for myopic choroidal neovascularization due to pathologic myopia: results from a post-marketing surveillance in Japan","volume":"32","author":"K Ohno-Matsui","year":"2018","journal-title":"Eye (Lond)"},{"issue":"3","key":"pone.0227557.ref026","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/eye.2010.226","article-title":"Prognostic factors for visual outcomes 2-years after intravitreal bevacizumab for myopic choroidal neovascularization","volume":"25","author":"H Nakanishi","year":"2011","journal-title":"Eye (Lond)"},{"issue":"1","key":"pone.0227557.ref027","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1159\/000333213","article-title":"Long-term follow-up of myopic choroidal neovascularization treated with ranibizumab","volume":"227","author":"N Franqueira","year":"2012","journal-title":"Ophthalmologica"},{"issue":"11","key":"pone.0227557.ref028","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1136\/bjophthalmol-2012-302973","article-title":"Intravitreal anti-VEGF therapy for choroidal neovascularisation secondary to pathological myopia: 4-year outcome","volume":"97","author":"JM Ruiz-Moreno","year":"2013","journal-title":"Br J Ophthalmol"},{"issue":"8","key":"pone.0227557.ref029","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1136\/bjophthalmol-2012-301639","article-title":"Long-term results of intravitreal bevacizumab for choroidal neovascularisation in pathological myopia","volume":"96","author":"M Gharbiya","year":"2012","journal-title":"Br J Ophthalmol"},{"key":"pone.0227557.ref030","article-title":"Ranibizumab versus verteporfin photodynamic therapy in Asian patients with myopic choroidal neovascularization: BRILLIANCE, a 12-month, randomized, double-masked study","author":"Y ST Chen","year":"2018","journal-title":"Retina"},{"key":"pone.0227557.ref031","first-page":"CD007419","article-title":"Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis","volume":"6","author":"G Virgili","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"pone.0227557.ref032","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2147\/OPTH.S151611","article-title":"Association of treatment adherence with real-life VA outcomes in AMD, DME, and BRVO patients","volume":"12","author":"C Ehlken","year":"2018","journal-title":"Clin Ophthalmol"},{"issue":"1","key":"pone.0227557.ref033","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1159\/000360307","article-title":"Anti-VEGF therapy in myopic choroidal neovascularization: long-term results","volume":"232","author":"P Freitas-da-Costa","year":"2014","journal-title":"Ophthalmologica"},{"key":"pone.0227557.ref034","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.2147\/OPTH.S135174","article-title":"Treatment of myopic choroidal neovascularization with intravitreal ranibizumab injections: the role of age","volume":"11","author":"D Karagiannis","year":"2017","journal-title":"Clin Ophthalmol"},{"issue":"6","key":"pone.0227557.ref035","article-title":"Prognostic factors of eyes with naive subfoveal myopic choroidal neovascularization after intravitreal bevacizumab","volume":"156","author":"HS Yang","year":"2013","journal-title":"Am J Ophthalmol"},{"issue":"9","key":"pone.0227557.ref036","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1097\/IAE.0b013e31821ba2dc","article-title":"Predictive factors for visual outcome to intravitreal bevacizumab in young Chinese patients with myopic choroidal neovascularization","volume":"31","author":"JZ Kuo","year":"2011","journal-title":"Retina"},{"issue":"12","key":"pone.0227557.ref037","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1007\/s00417-012-2159-5","article-title":"Summary of prognostic factors for choroidal neovascularization due to pathological myopia treated by intravitreal bevacizumab injection","volume":"250","author":"J Wang","year":"2012","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"pone.0227557.ref038","article-title":"Long-Term Outcomes of Ranibizumab Treatment of Myopic Choroidal Neovascularization in East-Asian Patients from the Radiance Study","author":"NW Tan","year":"2017","journal-title":"Retina"},{"issue":"12","key":"pone.0227557.ref039","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1097\/IAE.0000000000000610","article-title":"Factors Influencing Need for Retreatment and Long-Term Visual Outcome after Intravitreal Bevacizumab for Myopic Choroidal Neovascularization","volume":"35","author":"DS Ng","year":"2015","journal-title":"Retina"},{"key":"pone.0227557.ref040","article-title":"Utility of real-world evidence for evaluating anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration","author":"J Talks","year":"2019","journal-title":"Surv Ophthalmol"},{"issue":"1","key":"pone.0227557.ref041","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/S0002-9394(14)76891-6","article-title":"Prevalence of lattice degeneration and its relation to axial length in severe myopia","volume":"111","author":"JM Celorio","year":"1991","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"pone.0227557.ref042","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/00006982-199212010-00003","article-title":"Peripheral retinal changes and axial myopia","volume":"12","author":"L Pierro","year":"1992","journal-title":"Retina"},{"issue":"5","key":"pone.0227557.ref043","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1136\/bjo.53.5.300","article-title":"Peripheral retina in myopia. With particular reference to retinal breaks","volume":"53","author":"SW Hyams","year":"1969","journal-title":"Br J Ophthalmol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0227557","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,21]],"date-time":"2020-01-21T13:29:18Z","timestamp":1579613358000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0227557"}},"subtitle":[],"editor":[{"given":"Alfred S.","family":"Lewin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2020,1,21]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,1,21]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0227557","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,21]]}}}